First, we evaluated the sensitivity of XRN2-deficient lung and breast cancer cells against these clinically relevant PARP inhibitors and then delineated the cellular consequences of simultaneous XRN2 deficiency and loss of PARP1 catalytic function. The gene discussed is XRN2; the disease is breast cancer.